Q2 2022 Calithera Biosciences Inc Earnings Call
butt
The conference will begin shortly. To raise your hand during Q&A, you can dial star 11. The conference will begin shortly. To raise your hand during Q&A, you can dial star 11.
You may begin. Thank you operator. Good afternoon everyone and welcome to our second quarter 2022 conference. All joining me today are season. Amal crunchy.
Earlier this afternoon, the issue of personal within the community is an overview of the second quarter 2022 financial and operational result, which can be accessed through our website at calibar.com.
Before we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans and prospects that constitute full of these statements for purposes of the State Highway provisions under the private security litigation requirements of managing what we shall.
Actual results may differ materially from those indicated by these fully looking statements as a result of various important factors, including those discussed in other factor sections of the periodic filing for the FCC.
In addition, only four of the key statements or presenters only have the today should not be relied upon as representing our needs as if any subsequent date. While we may elect to update each or the key statements at some point in the future, we specifically display any opportunity to use those even if our needs change. Please note that this call is being recorded. And with that, I'll turn the call over to Susan.
Thanks, Stephanie. Good afternoon, everyone, and thank you for joining us for today's conference call.
When we spoke last quarter, I noted the caltera was off to an exciting start in 2022 and I'm pleased to say that this momentum has continued in recent months as we work to advance our pipeline of investigational small molecule oncology compounds to address needs of biomarker-defined patient populations.
The most notable developments, of course, were the initiations and enrollment of the first patients in our phase two clinical trials of MIVA Votingiv in relapse refractory non-GCV diffuse large B-cell lymphoma or DLBCL in June and sub-Hanniserative in relapse refractory nurse two mutated squamous and non-small cell lung cancer in the first week of July . The most notable symptoms, and non-small cell lung cancer first week of July .
We remain on track to report data from both of these monotherapy studies by the first quarter of 2023 and look forward to sharing additional details along the way.
Further, updates on both programs were shared at the Pan-Pacific Lymphoma Conference and the World Conference for Lung Cancer.
At the Pan Pacific Conference last month, Dr. Reem Carmali of Northwestern University presented a poster detailing the design of the Phase II Miser-Vote mixed study.
And just last week at World Long, Dr. Damas M
Preclinical studies show that combining pemiglenostat and sepenocertib demonstrated synergistic anti-tumor activity.
As you recall, we are not developing telogrenostat at this time. However, we are interested in this combination and look forward to the results of this investigator-initiated study.
Emma will provide more details on these presentations in his remarks.
We continue to believe that by focusing on well-characterized genetic vulnerabilities with molecules that have already shown single agent activity, we will be able to generate phase 2 data with targeted, efficient study designs such as those we are currently enrolling.
We believe that these studies have the potential to lead us to efficient paths to approval in biomarker-defined patient populations.
Turning to our preclinical programs, we have continued to advance our pipeline of synthetically high mortality targets, most notably VPS4a and VPS4b.
And as you heard on last quarter's earning call, we shared the first data from this program at AACR in April .
We are continuing to advance multiple compound series through lead optimization and look forward to updating you on our progress as we advance towards first in human clinical studies.
We expect to provide further updates on our preclinical efforts by year-end.
And with that said, I will pass the call over to Emil to provide additional details on our program.
Thank you, Susan. Looking first at our clinical programs, in July we announced the first patient enrolled to our Phase 2 clinical trial of Cetanocertid in relapse refractory nerve 2 or NFB2L2 mutated screen with non-small cell lung cancer.
As a reminder, the stapatosurgeon study is an open label monotherapy study in patients with nerve-to-mutated squamous non-small cell lung cancer whose disease has progressed on or after platinum doublet chemotherapy and immunotherapy.
The study is evaluating two doses of the panosertib, two milligrams twice daily and three milligrams once daily in patients with squamous non-small cell lung harboring either wild-type or mutated nerve 2 as detected by next-generation sequencing.
With this study, our goals are to refine dosing and confirm stent-a-ser to the selective activity in NRC2 mutated tumors compared to wild-type. The primary endpoints are investigator-assessed overall response rate and safety, with secondary endpoints including duration of response, PFS, and OS. We believe that the data from this study could position us to initiate a registrational study.
As Susan mentioned, earlier this month, dose escalation data from an investigator led multi-center phase 1-2 trial combining cepanoceratin and teloglenostat in biomarker-defined cohorts with patients with advanced non-small cell lung cancer were presented at the 2022 World Conference on Lung Cancer in Vienna. In preclinical studies, combining cepanoceratin and teloglenostat showed synergistic anti-tumor activities in keep or nurse mutated non-small cell lung cancer.
In the clinical trial, data on the first 13 patients in dose escalation showed the cepanocertic Pelleglansitin combination was well tolerated and also showed encouraging early evidence of clinical benefit, including a partial response in one patient with Nrf2 mutant squamous non-small lung cancer and stable disease with tumor shrinkage in a patient with KEEP1 and KRAS-mutated adenine squamous lung cancer.
The investigators are continuing dose escalation with the combination to determine the final recommended expansion dose. Upon determination of the final recommended expansion dose,
The study investigators plan to enroll patients into one of four expansion cohorts, evaluating cipenosarcoma plus teleglenostat in squamous non-small cell lung with and without Nrf2 or P1 mutation.
and lung adenoparsinoma with KRAS and KEEP1 or NERF2 mutations.
Now, turning to myvavotinib, we are conducting an open label monotherapy study in patients with relapsed or refractory non-GCB-DL-DCL. We're enrolling approximately 50 non-GCB-DL-DCL patients with or without MITEI 88 slash CD79D
who will be randomized into one of two dosing cohorts.
continuous dosing at 100 milligrams QA, or an induction dosing schedule of 120 milligrams Q-day for 14 days, followed by 80 milligrams Q-day starting on day 15. The objectives of this study are to confirm previously observed single agent activity in non-GCP-DL-DCL, determine activity in patients with MYD88 or CD79B mutated DLVCL, and further refine dose and schedule. MYD88 or CD79B mutation status will be determined using CT-
In July , we presented a trial in progress poster at the Pan Pacific Lymphoma Conference detailing the rationale and design of this phase 2 study based on a combined analysis of two prior studies of myelovotenin monotherapy in relapsed or refractory DLBCL. In these studies, myelovotenin at the recommended phase 2 dose of 100 mg Q daily showed a compelling overall response rate of 53% with a median duration of response of 15.7 months.
in non-GCB patients. In addition to the monotherapy study, we plan to pursue combination strategies aimed at evaluating myvovotinib with novel and standard of care therapies in earlier lines of DLBCL and other lymphomas. We look forward to sharing additional details on these plans as we advance further.
Turning to our preclinical development efforts, as Susan stated, we have continued to advance our pipeline of synthetic lethality targets. As a reminder, the data shared at the AACR annual meeting demonstrated the synthetic lethal interaction between gene paralogs VPS4A and VPS4B, validating these as attractive targets in tumors that have lost a fever paralog. These data were the first preclinical evidence supporting a newly discovered series of compounds in wo Harmonic.? ivory
designed to target these proteins for cancer treatment. We're currently advancing multiple theories to lead optimization and look forward to updating you on the program by the end of this year. With that, I'll pass it over to Stephanie for an update on our financials.
Thank you, Emily. An overview of financial results were included in today's press release. I will briefly review our results on this call.
Our cash and cash equivalent totaled $41.8 million on June 30, 2022, which we expect will be sufficient to meet our operating plan through the 7th quarter of 2023. Our ending expenses for the 2nd quarter 2022 were $7.8 million compared to $12.8 million in the same period last year. The decrease was primarily due to decreases in the telephone effect and CD280 program, partially offset by increases in the data sources and miles of it in the program.
DNA expenses for the second quarter of 2022 were 3.69 compared to 4.59 in the same year as last year. The decrease was primarily due to decreased personality related costs.
Other income net for the second quarter 2022 was $2.3 million, primarily attributable to the decrease in fair value of warrant liability.
Net loss for a three-month ended June 30, 2022 was 9.11. And with that, I will now return the call back over to Susan.
Thank you, Stephanie. And with that, operator, we're happy to open the line for questions.
As a reminder, to ask a question, please press star 11.
Our first question comes from Jonathan Chang with SDB Securities. Your line is open.
Hi guys, thanks for taking my questions.
First question, can you discuss the rationale for the doses being evaluated in the fipenacertib phase 2 study, and how do those compare to what was used in the recently presented World Lung Combination Study as well as other prior studies?
Sure, Jonathan, great question. The rationale for the monotherapy dose schedule is primarily the extensive amount of data we had from the monotherapy trials that Takeda had conducted as well as extensive PKPD modeling. In brief, that showed that the doses of 3 milligrams to 4 milligrams, you avoided the dose-limiting toxicity, the GI tox, and your primary AE was hyperglycemia, which is very manageable and did not lead to discontinuation.
six to seven hours. So you could get more exposure with the same safety profile. So that was the rationale for the monotherapy doses we're evaluating. In terms of their combination data just presented, they presented data on their first dose level is just two milligrams Q-Day combined with 800 milligrams CID of teleglenostat. So the starting doses are similar for cipanocerci. However, given that as a combination with two drugs, each of which have their own unique safety profile.
it's not exactly easy to extrapolate from combination safety data to the model of therapy. So we would consider those separate.
Understood. Makes sense. So maybe zooming out from the specific dosing question, what would you say are the key takeaways from the investigators study presented at World's Long-Lithopanaser to plus teloglenostat combination and what are the implications for your ongoing efforts?
Yeah, I think the main takeaway is given that it's still a small data set, dose escalation is that so far the combination looks very tolerable. And we're especially encouraged by the early clinical activity we're seeing. We think it's at least even at the small numbers and a total proof of concept again that a nerve-2-mutant squamous lung cancer patient had a partial response. So definitely encouraging on both fronts from safety and efficacy. And from a wider angle, I think that data complements nicely.
with the monotherapy data as we generate that to provide potential development paths for both mono and combo.
Got it. And just one last question for me. I know you guys just started the Phase 2 studies, but can you provide any color on at least the initial progress of those Phase 2 studies for sepanosertib and myelodontinib and just talk about your level of confidence that you guys will be able to provide meaningful updates by the first quarter of 23?
Right, so we're not providing detailed interim enrollment updates. I mean, I can tell you that we have started enrollment on both sites that are being activated and patients are actively being screened and enrolled. So again, as we said previously, given that we're really looking at populations where these two drugs have already shown single agent activity, we have a short time to response for both drugs, and we have a well-characterized safety profile. And these are the reasons we're still guiding to the data in first quarter 23.
Thanks for taking my questions.
Sure, thanks.
As a reminder, to ask a question, please press star 11.
Our next question comes from Roger Song with Jefferies. Your line is open.
Great. Thank you for taking the question. Maybe just follow up on the phase two data readouts. Maybe can you just comment on the expectation for the data readouts given you started and what will be the go no go decision criteria for the, if you will, have the first initial data readout and what will be considered as the winning scenario for the initial result. Thank you.
Yeah, I mean, again, to reiterate the point on the fact that the data that we're expecting or our response data based on efficacy data that we already have a bar for based on previous data from both drugs in these specific biomarker defined populations, we think that we can understand how the invited or the
We are still on track in terms of getting to meaningful data by 1Q23 based on the timing by which we started the enrollment and the rate at which we're opening sites. So aside from that, we haven't provided detailed guidance on exact numbers slash go, no-go decisions. Beyond that, we expect meaningful data by that time point. We expect meaningful data by that time point.
Understood. Okay. And then with the World Learn Conference, the combo data.
I think Sudha mentioned you're not planning to develop the glenostatte, teleglenostatte, standalone, but would you sponsor your own combo study or it may depend on the phase two splenostatte data, then you would decide if you will go with the combo. I think that's a good idea. I think that's a good idea.
Yeah, right. As Susan said, and we said we're not developing Telleglena set at this time with any sort of Calcare sponsored trials. But we're interested in the outcome of this IST. Our primary focus right now is on these monotherapy development paths for both the panic search and the myeloidinib. That's where our full focus and efforts are right now. But I think it'll be a nice complementary data set that reads out in parallel to both the monotherapy efforts that could guide us depending on how they look.
Okay, maybe last question from us is the financial, the cash runway, given you will read out data in 1Q and your current cash runway is to 2Q next year, just curious any flexibility in your cash runway will be or any other way to extend the current cash runway.
Got it? Thank you. That's all from us. Thank you. Thanks Roger.
There are no further questions. I'd like to turn the call back over to Susan Molino for any closing remarks.
Thank you and thanks for all joining us today. Have a good evening.
Thanks for all joining us today. Have a good evening. Bye, bye.
This concludes the program. You may now disconnect.
you
I.
And.
I.
Good day and welcome to the Calistair Biosciences second quarter 2022 Earnings Conference Hall. At this time all participants are in listen only mode.
After the speaker's presentation, there will be a question and answer session.
As a reminder, this call may be recorded. I would like to turn the call over to Stephanie Wong, CFO . You may begin.
Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2022 conference call. Joining me today are Susan Molyneux, founder, president and CEO , and Emil Carriacos, chief medical officer.
Earlier this afternoon, we issued a press release which included an overview of a second quarter 2022 financial and operational results which can be accessed through our website at caligaray.com.
Before we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans, and plastics that constitute forward-looking statements for purposes of the State Harbor Corridions under the Private Security Litigation Reform Act of 1985.
Actual results may differ materially from those indicated by these poorly looking statements as a result of various important factors, including those discussed in other sector sections of a periodic filing for the FCC.
In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Please note that this call is being recorded. And with that, I'll turn the call over to Susan.
Thanks, Stephanie. Good afternoon, everyone, and thank you for joining us for today's conference call.
When we spoke last quarter, I noted that caltera was off to an exciting start in 2022 and I'm pleased to say that this momentum has continued in recent months as we worked to advance our pipeline of investigational small molecule oncology compounds to address needs of biomarker-defined patient populations.
The most notable developments, of course, were the initiations and enrollment of the first patients in our phase 2 clinical trials of mivovotinib in relapsed refractory non-GCV diffuse large B cell lymphoma, or DLBCL, in June , and cepanocertib in relapsed refractory Nrf2 mutated squamous non-small cell lung cancer in the first week of July .
We remain on track to report data from both of these monotherapy studies by the first quarter of 2023 and look forward to sharing additional details along the way.
Further, updates on both programs were shared at the Pan-Pacific Lymphoma Conference and the World Conference for Lung Cancer.
At the Pan Pacific Conference last month, Dr. Reem Karmali of Northwestern University presented a poster detailing the design of the Phase II microvotonic study.
And just last week at World Long, Dr. Damas Moulis of UC Davis Comprehensive Cancer Center presented during a mini oral session the findings from an investigator initiated multi-center phase one two-dose escalation study of Cipen's circuit in combination with telglenostat in advanced non-small cell lung cancer patients.
Preclinical studies show that combining pemiglenostat and sepenocertib demonstrated synergistic anti-tumor activity.
As you recall, we are not developing teloglenostat at this time. However, we are interested in this combination and look forward to the results of this investigator-initiated study.
Emma will provide more details on these presentations in his remarks.
We continue to believe that by focusing on well-characterized genetic vulnerabilities with molecules that have already shown single agent activity, we will be able to generate phase two data with targeted efficient study designs, such as those we are currently enrolling.
We believe that these studies have the potential to lead us to efficient paths to approval in biomarker-defined patient populations.
Turning to our preclinical programs, we have continued to advance our pipeline of synthetically salivary targets, most notably VPS4A and VPS4B.
And as you heard on last quarter's earning call, we shared the first data from this program at AACR in April .
We are continuing to advance multiple compound series through lead optimization and look forward to updating you on our progress as we advance towards first in human clinical studies.
We expect to provide further updates on our preclinical efforts by year-end.
And with that said, I will pass the call over to Emil to provide additional details on our program.
Thank you, Susan. Looking first at our clinical programs, in July we announced the first patient enrolled to our Phase 2 clinical trial of cetanic sertid in relapsed refractory Nrf2 or NFB2L2 mutated with screen and non-small cell lung cancer.
As a reminder, the Sipanisertib study is an open-label monotherapy study in patients with nerve-2 mutated squamous non-small cell lung cancer, whose disease has progressed on or after platinum doublet chemotherapy and immunotherapy. The study is evaluating two doses of Sipanisertib, 2 mg twice daily and 3 mg once daily, in patients with squamous non-small cell lung, harbouring either wild-type or mutated nerve-2 as detected by next-generation sequencing.
With this study, our goals are to refine dosing and confirm stent to selective activity in nerve-to-mutated tumors compared to wild types. The primary endpoints are investigator-assessed overall response rate and safety, with secondary endpoints including duration of response, PFS, and OS. We believe that the data from this study could position us to initiate a registrational study.
As Susan mentioned, earlier this month, dose escalation data from an investigator led multi-center phase 1-2 trial combining cetanocertib and teleglenostat in biomarker-defined cohorts with patients with advanced non-small cell lung cancer were presented at the 2022 World Conference on Lung Cancer in Vienna. In preclinical studies, combining cetanocertib and teleglenostat showed synergistic anti-tumor activity in keep or nurse mutated non-small cell lung cancer.
In the clinical trial, data on the first 13 patients in dose escalation showed the cepanocertic preleglanostat combination was well tolerated and also showed encouraging early evidence of clinical benefit, including a partial response in one patient with Nrf2 mutant squamous non-small small lung cancer and stable disease with tumor shrinkage in a patient with KEEP1 and Keras mutated adenoscremous lung cancer.
Investigators are continuing dose escalation with the combination to determine the final recommended expansion dose. Upon determination of the final recommended expansion dose,
The study investigators plan to enroll patients into one of four expansion cohorts, evaluating cipenosarcoma plus teleglenostat in squamous non-small cell lung with and without Nrf2 for keep on mutation.
and lung adenoparsinoma with KRAS and KEE-1 or NERF-2 mutations.
Now, turning to myovotinib, we are conducting an open label monotherapy study in patients with relapsed or refractory non-GCB-DL-DCL. We're enrolling approximately 50 non-GCB-DL-DCL patients with or without MITEI-ADA-CD79-B in the occasion.
who will be randomized into one of two dosing cohorts.
continuous dosing at 100 milligrams QA, or an induction dosing schedule of 120 milligrams QA for 14 days, followed by 80 milligrams QA starting on day 15. The objectives of this study are to confirm previously observed single agent activity in non-GCP-DL-DCL, determine activity in patients with MyD88 or CD79B mutated DLVCL, and further refine dose and schedule. MyD88 or CD79B mutation status will be determined using CT DNA-based liquid.
a trial-in-progress poster at the Pan-Pacific Lymphoma Conference detailing the rationale and design of this phase 2 study based on a combined analysis of two prior studies of myvavotinin monotherapy in relapsed or refractory DLBCL. In these studies, myvavotinin at the recommended phase 2 dose of 100 mg Q daily showed a compelling overall response rate of 53% with a median duration of response of 15.7 months in non-GCB patients.
In addition to the monotherapy study, we plan to pursue combination strategies aimed at evaluating myvovotinib with novel and standard of care therapies in earlier lines of DLBCL and other lymphomas. We look forward to sharing additional details on these plans as we advance further.
Turning to our preclinical development efforts, as Susan stated, we have continued to advance our pipeline of synthetic lethality targets. As a reminder, the data shared at the AACR annual meeting demonstrated the synthetic lethal interaction between gene paralogs, VPS4A and VPS4B, validating these as attractive targets in tumors that have lost a fever paralog. These data were the first preclinical evidence supporting a newly discovered series of compounds designed to target these proteins for cancer treatment.
We're currently advancing multiple theories to lead optimization and look forward to updating you on the program by the end of this year. With that, I'll pass it over to Stephanie for an update on our financials.
Thank you, Ed. An overview of financial results were included in today's press release. I will briefly review our results on this call.
Our cash and cash equivalents totaled $41.8 million on June 30, 2022, which we expect will be sufficient to meet our operating plan through the 7th quarter of 2023. Our ending expenses for the 2nd quarter 2022 were $7.8 million compared to $12.8 million in the same period last year. The decrease was primarily due to decreases in the telephone effect and CD280 program, partially offset by increases in the Santa Teresa and Miserable program.
DNA expenses for the second quarter of 2022 were 3.69 compared to 4.59 in the same year as last year. The decrease was primarily due to decreased personality later costs.
Other income net for the second quarter 2022 was $2.3 million, primarily attributable to the decrease in fair value of warrant liabilities. Net loss for the three months ended June 30, 2022 was $9.1 million. And with that, I will now return the call back over to Susan.
Thank you, Stephanie. And with that, operator, we're happy to open the line for questions.
As a reminder, to ask a question, please press star 11.
Our first question comes from Jonathan Chang with SDB Securities. Your line is open.
Hi guys, thanks for taking my questions.
First question, can you discuss the rationale for the doses being evaluated in the fipenacertib phase 2 study, and how do those compare to what was used in the recently presented World Lung Combination study as well as other prior studies?
Sure, Jonathan, great question. The rationale for the monotherapy dose schedule is primarily the extensive amount of data we had from the monotherapy trials that Takeda had conducted as well as extensive PKPD modeling. In brief, that showed that the doses of 3 milligrams to 4 milligrams, you avoided the dose-limiting toxicity, the GI tox, and your primary AE was hyperglycemia, which is very manageable and did not lead to discontinuation.
And so we already also saw that aside from the safety profile that that was an active dose in the study run by Paul. Take we're also evaluating 2 milligrams again, based on the safety modeling, given that are not too much related. That you can get to a higher cumulative dose of 4 milligrams with the schedule given that the drug has a half life around 6 to 7 hours.
So you could get more exposure with the same safety profile. So that was the rationale for the monotherapy doses we're evaluating. In terms of their combination data just presented, they presented data on their first dose level is just two milligrams Q-Day combined with 800 milligrams CID of teleglenostat. So the starting doses are similar for satanic circuit. However, given that as a combination with two drugs, each of which have their own unique safety profile.
it's not exactly easy to extrapolate from combination safety data to the model of therapy. So we would consider those separate.
Understood. Makes sense. So maybe zooming out from the specific dosing question, what would you say are the key takeaways from the investigators study presented at World Law, the cepanaser plus teleglenostat combination, and what are the implications for your ongoing efforts?
Yeah, I think the main takeaway is given that it's still a small data set, dose escalation as of so far, the combination looks very tolerable. And we're especially encouraged by the early clinical activity we're seeing. We think it's, at least even at the small numbers, anecdotal proof of concept again that a nerve-2-mutant squamous lung cancer patient had a partial response. So definitely encouraging on both fronts from safety and efficacy.
And from a wider angle, I think that data complements nicely with the monotherapy data as we generate that to provide potential development paths for both mono and combo.
Got it. And just one last question for me. I know you guys just started the Phase 2 studies, but can you provide any color on at least the initial progress of those Phase 2 studies for sepanosertib and myelodontinib? And just talk about your level of confidence that you guys will be able to provide meaningful updates by the first quarter of 23.
Right. So, we're not providing detailed interim enrollment updates. I mean, I can tell you that we have started enrollment on both sites that are being activated and patients are actively being screened and enrolled. So, again, as we said previously, given that we're really looking at populations where these two drugs have already shown single agent activity, we have a short time to response for both drugs, and we have a well-characterized AP profile, and these are the reasons we're still guiding to the data in first quarter 23.
Thanks for taking my questions.
As a reminder, to ask a question, please press star 11.
Our next question comes from Roger Song with Jeffries. Your line is open.
Great. Thank you for taking the question. Maybe just follow up on the phase two data readouts. Maybe can you just comment on the expectation for the data readouts, given you started, and what will be the go-no-go decision criteria for the, if you will, have the first initial data readout, and what will be considered as the winning scenario for the initial readout. Thank you.
Yeah, I mean, again, to reiterate the point on the fact that the data that we're expecting or our response data based on efficacy data that we already have a bar for based on previous data from both drugs in these specific biomarker defined populations, we think that we can
We are still on track in terms of getting to Meaningful Data by 1Q23 based on the timing by which we started the enrollment and the rate at which we're opening sites. So aside from that, we haven't provided detailed guidance on exact numbers slash go, no-go decisions. Beyond that, we expect Meaningful Data by that time point. For more information or to receive updates on Morningmail gladly visit RyanSont Fault. Network meet with Ryan in board box April 28, 2014
Understood. Okay. And then with the World Learn Conference, the combo data.
I think that Sudha mentioned you're not planning to develop the glenostatte, teleglenostatte, standalone. But would you sponsor your own combo study? Or it may depend on the phase 2 splenostatte data and then you will decide if you will go with the combo.
Yeah, right. As Susan said, and we said we're not developing Telleglena set at this time with any sort of Calcare sponsored trials. But we're interested in the outcome of this IST. Our primary focus right now is on these monotherapy development tasks for both the panic surgery and myeloidinib. That's where our full focus and efforts are right now. But I think it'll be a nice complementary data set that reads out in parallel to both of the monotherapy efforts that could guide us depending on how they look.
Okay, maybe last question from us is the financial, the cash runway. Given you will read out data in one queue and your current cash runway is to two queue next year, just curious any flexibility your cash runway will be or any other way to extend the current cash runway.
to go a little bit further beyond the data catalyst. Hi, Roger. Stephanie, thanks for the question. We certainly are evaluating the cash runway continuously and also we're mindful of making sure that we can execute these programs. So as we make decisions, we will update everyone on any changes to our poem.
Thank you. That's all on us. Thank you. Thanks, Roger. Thank you.
There are no further questions. I'd like to turn the call back over to Susan Molino for any closing remarks.
Thank you and thanks for all joining us today. Have a good evening.
Thank you and thanks for all joining us today. Have a good evening.
This concludes the program. You may now disconnect.